CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 440 enrolled
Drug / intervention
repaglinide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01022762
NCT01022762Phase 4Completed
CompareCT.gov

A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naïve Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Dec 1, 2009·Updated Jul 9, 2014

In Brief

A Phase 4 clinical trial evaluating repaglinide and gliclazide for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 440 participants across 1 site.

Detailed Summary

This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood glucose lowering effect and the safety profile of repaglinide given alone compared to gliclazide given alone in Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs (OADs). This study also investigates the augment effect of repaglinide on the phases of insulin secretion as a subgroup study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 1, 2009
Enrollment StartNov 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.6 years ago

Interventions

repaglinidedrug

Individually adjusted dose for 16 weeks

gliclazidedrug

Individually adjusted dose for 16 weeks